[NCI CIRB] A031704 - PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
The purpose of this study is to determine if adding a drug called cabozantinib to another treatment after receiving the standard treatment can prolong the life of patients with advanced kidney cancer. The study is also trying to determine if this approach is better or worse than the usual approach.
Renal Cell Carcinoma
1- Histologically documented renal cell carcinoma with clear cell component, including patients who have sarcomatoid features.
2- Measurable Disease
3- No prior treatment with PD-1, PD-L1, or CTLA-4 targeting agents; No prior previous systemic therapy for renal cell carcinoma; No cancer therapy less than 28 days prior to registration
4- Over the age of 18 years
5- Not pregnant or nursing
6- Laboratory values within range
18 - 99
Healthy Volunteers Needed
Duration of Participation
5 years from registration
Knight Information Line - firstname.lastname@example.org or 503-494-1080